Malignant otitis externa

Summary

Malignant otitis externa (MONDO:0001050) is a disease and 2 clinical trials. Top therapeutic interventions include oxygen. A subtype of otitis externa — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant otitis externa
Mondo ID	MONDO:0001050
DOID	DOID:10516
ICD-10-CM	H60.2
ICD-11	984580942
SNOMED CT	94146005
UMLS	C0155395
MedGen	509950
Is cancer (heuristic)	no

Disease family

This is a subtype of otitis externa. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorder › external ear disorder › otitis externa › malignant otitis externa

Related subtypes (3): otomycosis, acute otitis externa, perichondritis of auricle

Subtypes (1): malignant otitis externa caused by Pseudomonas aeruginosa

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07240649	PHASE4	NOT_YET_RECRUITING	Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
NCT05994768	Not specified	COMPLETED	18F-FDG Tomography and Labeled Leukocyte Scintigraphy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
OXYGEN	4	1